oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2021-20-5-49-57oncotomsk-1915Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESРОЛЬ EZH2 И ARID1A В ДИАГНОСТИКЕ ПЛОСКИХ УРОТЕЛИАЛЬНЫХ ОПУХОЛЕЙ С АТИПИЕЙTHE ROLE OF EZH2 AND ARID1A IN THE DIAGNOSIS OF FLAT UROTHELIAL LESIONS WITH ATYPhttps://orcid.org/0000-0002-2936-5631SamehR.SamehR.

MD, ассистент, кафедра патологии, факультет медицины человека,

Загазиг, 44519, Аш-Шарика

MD, Assistant, Lecturer, Pathology Department, Faculty of Human Medicine,

Zagazig, 44519, Al-Sharika

Rehamsameh99@gmail.comhttps://orcid.org/0000-0001-5359-0209MostafaN.MostafaN.

MD, профессор, кафедра патологии, факультет медицины человека, 

Загазиг, 44519, Аш-Шарика

MD, Professor, Pathology Department, Faculty of Human Medicine,

Zagazig, 44519, Al-Sharika

Dr.embaby@yahoo.comhttps://orcid.org/0000-0002-9078-0463EmbabyA.EmbabyA.

MD, отделение клинической гематологии, отделение внутренней медицины, факультет медицины человека,

Загазиг, 44519, Аш-Шарика

MD, Lecturer, Clinical Hematology Unit, Internal Medicine Department, Faculty of Human Medicine,

Zagazig, 44519, Al-Sharika

https://orcid.org/0000-0002-9078-0463RaoufS. A.RaoufS. A.

MD, отделение клинической гематологии, отделение внутренней медицины, факультет медицины человека,

Загазиг, 44519, Аш-Шарика

MD, Assistant, Professor, Pathology Department, Faculty of Human Medicine,

Zagazig, 44519, Al-Sharika

Dr.embaby@yahoo.comhttps://orcid.org/0000-0002-5381-8717AbdelwahabK.AbdelwahabK.

MD, доцент, отделение урологии, факультет медицины человека, 

Загазиг, 44519, Аш-Шарика

MD, Assistant, Professor, Urology Department, Faculty of Human Medicine,

Zagazig, 44519, Al-Sharika

Загазигский университетЕгипетZagazig UniversityEgypt2021281020212054957Copyright © Sameh R., Mostafa N., Embaby A., Raouf S.A., Abdelwahab K., 20212021Sameh R., Mostafa N., Embaby A., Raouf S.A., Abdelwahab K.Sameh R., Mostafa N., Embaby A., Raouf S.A., Abdelwahab K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1915Актуальность

Актуальность. Диагностика уротелиальной карциномы in situ имеет большое значение, поскольку обладает прогностической и терапевтической ценностью.

Целью исследования было определить роль EZH2 и ARID1A в диагностике карциномы in situ.

Материал и методы

Материал и методы. Ретроспективное перекрестное исследование включало 24 образца плоских уротелиальных опухолей, 20 образцов CIS и 10 образцов нормального прилегающего уротелия, взятых при цистоскопической биопсии. Во всех случаях была оценена иммуногистохимическая экспрессия EZH2 и ARID1A.

Результаты

Результаты. Все образцы нормального уротелия показали высокое ядерное окрашивание на ARID1A и отрицательное ядерное окрашивание на EZH2. Высокая экспрессия EZH2 наблюдалась в 80 % образцов CIS по сравнению с 20 % плоских уротелиальных опухолей с атипией (p=0,001), в то время как высокая экспрессия ARID1A наблюдалась в 70,8 % плоских уротелиальных опухолей с атипией по сравнению с 25 % образцов CIS (р=0,001). EZH2 был более точным и специфичным при диагностике карциномы in situ.

Заключение

Заключение. EZH2 и ARID1A являются перспективными диагностическими маркерами уротелиальной карциномы in situ. EZH2 более точен и специфичен, чем ARID1A, в диагностике карциномы in situ по сравнению с другими плоскими уротелиальными опухолями. 

Background

Background. Diagnosis of urothelial carcinoma in situ is of great importance because it has prognostic and therapeutic value.

We aim to determine the utility of EZH2 and ARID1A as a new tool in the diagnosis of carcinoma in situ.

Material and Methods

Material and Methods. This retrospective cross-sectional study included Twenty-four specimens of flat urothelial lesions, twenty specimens of CIS, and 10 of normal adjacent urothelium that was taken by cystoscopic resection biopsy procedure. immunohistochemical expression of EZH2 and ARID1A. were evaluated in all studied cases.

Results

Results. All normal urothelium specimens showed high nuclear staining for ARID1A and negative nuclear staining for EZH2. High EZH2 expression was observed in 80 % of CIS specimens compared to 20 % of flat urothelial lesions with atypia (p=0.001 ), while high ARID1A expression was observed in 70.8 % of flat urothelial lesions with atypia compared to 25 % of CIS specimens (p=0.001). EZH2 was more accurate and specific in the diagnosis of carcinoma in situ.

Conclusion

Conclusion. EZH2 and ARID1A are promising diagnostic markers for urothelial CIS. EZH2 is more accurate and specific than ARID1A in the diagnosis of carcinoma in situ versus other flat urothelial lesions. 

дисплазиякарцинома in situреактивная атипияEZH2ARID1Aиммуногистохимияdysplasiacarcinoma in situreactive atypiaEZH2ARID1AimmunohistochemistryReferencesFerlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15; 144(8): 1941–1953. doi: 10.1002/ijc.31937.Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15; 144(8): 1941–1953. doi: 10.1002/ijc.31937.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.Cheng L., Lopez-Beltran A., MacLennan G.T., Montironi R., Bostwick D.G. Neoplasms of the urinary bladder. Urologic Surgical Pathology. Elsevier, 2008. p. 258–351.Cheng L., Lopez-Beltran A., MacLennan G.T., Montironi R., Bostwick D.G. Neoplasms of the urinary bladder. Urologic Surgical Pathology. Elsevier, 2008. p. 258–351.Humphrey P.A., Moch H., Cubilla A.L., Ulbright T.M., Reuter V.E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul; 70(1): 106–119. doi: 10.1016/j.eururo.2016.02.028.Humphrey P.A., Moch H., Cubilla A.L., Ulbright T.M., Reuter V.E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul; 70(1): 106–119. doi: 10.1016/j.eururo.2016.02.028.Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul; 70(1): 93–105. doi: 10.1016/j.eururo.2016.02.029.Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul; 70(1): 93–105. doi: 10.1016/j.eururo.2016.02.029.Nguyen J.K., Przybycin C.G., McKenney J.K., Magi-Galluzzi C. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Hum Pathol. 2020; 98: 81–88. doi: 10.1016/j.humpath.2020.02.008.Nguyen J.K., Przybycin C.G., McKenney J.K., Magi-Galluzzi C. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Hum Pathol. 2020; 98: 81–88. doi: 10.1016/j.humpath.2020.02.008.Poropatich K., Yang J.C., Goyal R., Parini V., Yang X.J. Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections. Diagn Pathol. 2016 Jun; 11(1): 57. doi: 10.1186/s13000-016-0501-7.Poropatich K., Yang J.C., Goyal R., Parini V., Yang X.J. Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections. Diagn Pathol. 2016 Jun; 11(1): 57. doi: 10.1186/s13000-016-0501-7.Lowenthal B.M., Sahoo D., Amin M.B., Hansel D.E. Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia. Arch Pathol Lab Med. 2020; 144(7): 853–62. doi: 10.5858/arpa.2019-0005-OA.Lowenthal B.M., Sahoo D., Amin M.B., Hansel D.E. Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia. Arch Pathol Lab Med. 2020; 144(7): 853–62. doi: 10.5858/arpa.2019-0005-OA.Cheng L., Zhang S., MacLennan G.T., Williamson S.R., LopezBeltran A., Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011 Apr; 42(4): 455–81. doi: 10.1016/j.humpath.2010.07.007.Cheng L., Zhang S., MacLennan G.T., Williamson S.R., LopezBeltran A., Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011 Apr; 42(4): 455–81. doi: 10.1016/j.humpath.2010.07.007.Takenaka A., Yamada Y., Miyake H., Hara I., Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008 Apr; 15(4): 309–13. doi: 10.1111/j.1442-2042.2008.02012.x.Takenaka A., Yamada Y., Miyake H., Hara I., Fujisawa M. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008 Apr; 15(4): 309–13. doi: 10.1111/j.1442-2042.2008.02012.x.Warrick J.I., Raman J.D., Kaag M., Bruggeman T., Cates J., Clark P., DeGraff D.J. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. Urol Oncol. 2016 Jun; 34(6): 258.e1-6. doi: 10.1016/j.urolonc.2016.02.011.Warrick J.I., Raman J.D., Kaag M., Bruggeman T., Cates J., Clark P., DeGraff D.J. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer. Urol Oncol. 2016 Jun; 34(6): 258.e1-6. doi: 10.1016/j.urolonc.2016.02.011.Pavlidou E.N., Balis V. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes. World Acad Sci J. 2020; 2: 49–64. doi: 10.3892/wasj.2020.37.Pavlidou E.N., Balis V. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes. World Acad Sci J. 2020; 2: 49–64. doi: 10.3892/wasj.2020.37.Liu X., Wu Q., Li L. Functional and therapeutic significance of EZH2 in urological cancers. Oncotarget. 2017 Jun 6; 8(23): 38044–38055. doi: 10.18632/oncotarget.16765.Liu X., Wu Q., Li L. Functional and therapeutic significance of EZH2 in urological cancers. Oncotarget. 2017 Jun 6; 8(23): 38044–38055. doi: 10.18632/oncotarget.16765.Kelso T.W.R., Porter D.K., Amaral M.L., Shokhirev M.N., Benner C., Hargreaves D.C. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017 Oct 2; 6: e30506. doi: 10.7554/eLife.30506.Kelso T.W.R., Porter D.K., Amaral M.L., Shokhirev M.N., Benner C., Hargreaves D.C. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017 Oct 2; 6: e30506. doi: 10.7554/eLife.30506.Suryo Rahmanto Y., Jung J.G., Wu R.C., Kobayashi Y., Heaphy C.M., Meeker A.K., Wang T.L., Shih Ie.M. Inactivating ARID1A Tumor Sup pressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. J Biol Chem. 2016 Apr 29; 291(18): 9690–9. doi: 10.1074/jbc.M115.707612.Suryo Rahmanto Y., Jung J.G., Wu R.C., Kobayashi Y., Heaphy C.M., Meeker A.K., Wang T.L., Shih Ie.M. Inactivating ARID1A Tumor Sup pressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. J Biol Chem. 2016 Apr 29; 291(18): 9690–9. doi: 10.1074/jbc.M115.707612.Luchini C., Veronese N., Solmi M., Cho H., Kim J.H., Chou A., Gill A.J., Faraj S.F., Chaux A., Netto G.J., Nakayama K., Kyo S., Lee S.Y., Kim D.W., Yousef G.M., Scorilas A., Nelson G.S., Köbel M., Kalloger S.E., Schaeffer D.F., Yan H.B., Liu F., Yokoyama Y., Zhang X., Pang D., Lichner Z., Sergi G., Manzato E., Capelli P., Wood L.D., Scarpa A., Correll C.U. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and metaanalysis. Oncotarget. 2015 Nov 17; 6(36): 39088–97. doi: 10.18632/oncotarget.5142.Luchini C., Veronese N., Solmi M., Cho H., Kim J.H., Chou A., Gill A.J., Faraj S.F., Chaux A., Netto G.J., Nakayama K., Kyo S., Lee S.Y., Kim D.W., Yousef G.M., Scorilas A., Nelson G.S., Köbel M., Kalloger S.E., Schaeffer D.F., Yan H.B., Liu F., Yokoyama Y., Zhang X., Pang D., Lichner Z., Sergi G., Manzato E., Capelli P., Wood L.D., Scarpa A., Correll C.U. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and metaanalysis. Oncotarget. 2015 Nov 17; 6(36): 39088–97. doi: 10.18632/oncotarget.5142.Li J., Lu S., Lombardo K., Monahan R., Amin A. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma. Hum Pathol. 2016 Sep; 55: 17–23. doi: 10.1016/j.humpath.2016.04.006.Li J., Lu S., Lombardo K., Monahan R., Amin A. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma. Hum Pathol. 2016 Sep; 55: 17–23. doi: 10.1016/j.humpath.2016.04.006.Zhou X., Liu N., Zhang J., Ji H., Liu Y., Yang J., Chen Z. Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population. Sci Rep. 2018 Dec; 8(1): 17792. doi: 10.1038/s41598-018-36164-y.Zhou X., Liu N., Zhang J., Ji H., Liu Y., Yang J., Chen Z. Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population. Sci Rep. 2018 Dec; 8(1): 17792. doi: 10.1038/s41598-018-36164-y.Kunju L.P., Lee C.T., Montie J., Shah R.B. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005 May; 55(5): 248–54. doi: 10.1111/j.1440-1827.2005.01821.x.Kunju L.P., Lee C.T., Montie J., Shah R.B. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005 May; 55(5): 248–54. doi: 10.1111/j.1440-1827.2005.01821.x.Lopez-Beltran A., Henriques V., Montironi R., Cimadamore A., Raspollini M.R., Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019 Jan; 74(1): 77–96. doi: 10.1111/his.13752.Lopez-Beltran A., Henriques V., Montironi R., Cimadamore A., Raspollini M.R., Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019 Jan; 74(1): 77–96. doi: 10.1111/his.13752.Cao Q., Wang C., Ding Y., Xu D., Qian S., Shen H., Qi J. ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma. J Int Med Res. 2020 Apr; 48(4): 300060519895687. doi: 10.1177/0300060519895687.Cao Q., Wang C., Ding Y., Xu D., Qian S., Shen H., Qi J. ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma. J Int Med Res. 2020 Apr; 48(4): 300060519895687. doi: 10.1177/0300060519895687.McKenney J.K., Desai S., Cohen C., Amin M.B. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001 Aug; 25(8): 1074–8. doi: 10.1097/00000478-200108000-00013.McKenney J.K., Desai S., Cohen C., Amin M.B. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001 Aug; 25(8): 1074–8. doi: 10.1097/00000478-200108000-00013.Ang P.P., Tan G.C., Karim N., Wong Y.P. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology. Acta Cytol. 2020; 64(3): 248–255. doi: 10.1159/000501406.Ang P.P., Tan G.C., Karim N., Wong Y.P. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology. Acta Cytol. 2020; 64(3): 248–255. doi: 10.1159/000501406.Raffone A., Travaglino A., Saccone G., Cieri M., Mascolo M., Mollo A., Insabato L., Zullo F. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019 Sep; 127(9): 597–606. doi: 10.1111/apm.12977.Raffone A., Travaglino A., Saccone G., Cieri M., Mascolo M., Mollo A., Insabato L., Zullo F. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019 Sep; 127(9): 597–606. doi: 10.1111/apm.12977.Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1): 8570–6. doi: 10.1158/1078-0432.CCR-05-1047.Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1): 8570–6. doi: 10.1158/1078-0432.CCR-05-1047.Aso T., Uozaki H., Morita S., Kumagai A., Watanabe M. Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. Anticancer Res. 2015 Dec; 35(12): 6819–27.Aso T., Uozaki H., Morita S., Kumagai A., Watanabe M. Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. Anticancer Res. 2015 Dec; 35(12): 6819–27.Alldredge J.K., Eskander R.N. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract. 2017 Oct 31; 4: 17. doi: 10.1186/s40661-017-0052-y.Alldredge J.K., Eskander R.N. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract. 2017 Oct 31; 4: 17. doi: 10.1186/s40661-017-0052-y.

The authors declare that there are no conflicts of interest present.